Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02977780 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT02977780 · ClinicalTrials.gov record · last posted 2026-08-19

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

Name: INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) — clinical trial record (NCT02977780)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 2

SponsorDavid Reardon, MD

Started2017-02-09

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This research study is studying several investigational drugs as a possible treatment for Glioblastoma (GBM). The drugs involved in this study are : * Abemaciclib (arm is currently closed to accrual) * Temozolomide (temodar) * Neratinib (arm is currently closed to accrual) * CC115 (arm is currently closed to accrual) * QBS10072S

Protocol amendment history 1 change detected by DataLookout

2026-08-20

Sponsor changed: Patrick Wen, MD → David Reardon, MD

Was~~Patrick~~ ~~Wen~~, MD

NowDavid Reardon, MD

Trial Details

NCT Number	NCT02977780
Lead Sponsor	David Reardon, MD Collaborators: Eli Lilly and Company, Celgene, Puma Biotechnology, Inc., Accelerate Brain Cancer Cure, Quadriga Biosciences, Inc.
Conditions	Glioblastoma
Enrollment	460 participants
Start Date	2017-02-09
Primary Completion	2028-02-01 (estimated)
Study Completion	2028-04-30 (estimated)
Updated on ClinicalTrials.gov	2026-08-19